COVID-19: A Single-Center ICU Experience of the First Wave in the Philippines

Table 2

Variables and SARS-CoV-2 status.

	SARS-CoV-2 positive (n = 31)	SARS-CoV-2 negative (n = 60)	Significance (two-tailed)
Demographics
Age (years)	65 (±12)	65 (±15)	0.918
Gender (% of males)	58.1%	65%	0.648
SAPS-3	56.5 (±16.3)	50.6 (±15.5)	0.102
Comorbidities
Neurologic			0.078
Yes	2 (6.5%)	13 (21.7%)
No	29 (93.5%)	47 (78.3%)
Cardiovascular			0.112
Yes	21 (67.7%)	50 (83.3%)
No	10 (32.3%)	10 (16.7%)
Pulmonary			0.061
Yes	6 (19.4%)	24 (40%)
No	25 (80.6%)	36 (60%)
Renal			<0.001
Yes	2 (6.5%)	27 (45%)
No	29 (93.5%)	33 (55%)
Endocrine			0.657
Yes	15 (48.4%)	25 (41.7%)
No	16 (51.6%)	35 (58.3%)
Autoimmune			0.713
Yes	2 (6.5%)	7 (11.7%)
No	29 (93.5%)	53 (88.3%)
Malignancy			0.320
Yes	2 (6.5%)	9 (15%)
No	29 (93.5%)	51 (85%)
Laboratories on ICU admission
Hemoglobin (g/L)	135 (±17)	120 (±31)	0.002
WBC count (×10^3/µL)	8.5 (±4.6)	13 (±9)	0.003
Platelets (×10^9/L)	220 (±75)	238 (±109)	0.382
PF ratio	163 (±103)	255 (±141)	0.002
Lactate (mmoL/L)	2 (±2)	2.9 (±2)	0.113
Treatment strategy
Hydroxychloroquine			<0.001
Yes	25 (80.6%)	9 (15%)
No	6 (19.4%)	51 (85%)
Tocilizumab			<0.001
Yes	17 (54.8%)	2 (3.3%)
No	14 (45.2%)	68 (96.7%)
Lopinavir/ritonavir			0.006
Yes	6 (19.4%)	1 (1.7%)
No	25 (80.6%)	59 (98.3%)
CRRT			<0.001
Yes	18 (58.1%)	10 (16.7%)
No	13 (41.9%)	50 (83.3%)
NMBA			0.017
Yes	6 (19.4%)	2 (3.3%)
No	25 (80.6%)	58 (96.7%)
Prone positioning			<0.001
Yes	13 (41.9%)	3 (5%)
No	18 (58.1%)	57 (95%)
IVIG			0.037
Yes	3 (9.7%)	0
No	28 (90.3%)	60 (100%)
HA-330			<0.001
Yes	8 (25.8%)	0
No	23 (74.2%)	60 (100%)
Intubation			<0.001
Yes	29 (93.5%)	34 (56.7%)
No	2 (6.5%)	26 (43.3%)
Outcomes			<0.001
ICU survivor	9 (29%)	45 (75%)
ICU mortality	22 (71%)	15 (25%)
Number of days intubated	13 (±7)	8 (±7)	0.005
Standardized mortality ratio	2.34	1.15